Johnson & Johnson has the distinction of a late-breaking presentation on June 5 for the first quantitative data from its CASTOR study of Darzalex (daratumumab) in patients with relapsed/refractory multiple myeloma.
Darzalex received accelerated approval in November 2015 well ahead of schedule as a fourth-line treatment for multiple myeloma, but positive...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

